Halozyme Therapeutics, Inc. (HALO)
61.91
-0.74
(-1.18%)
USD |
NASDAQ |
Dec 11, 16:00
61.91
0.00 (0.00%)
After-Hours: 20:00
Halozyme Therapeutics Free Cash Flow: 602.40M for Sept. 30, 2025
Free Cash Flow Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| Merck & Co., Inc. | 13.05B |
| ANI Pharmaceuticals, Inc. | 136.04M |
| Bristol Myers Squibb Co. | 15.30B |
| Twist Bioscience Corp. | -75.63M |
| Aurinia Pharmaceuticals, Inc. | 120.39M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | 178.60M |
| Cash from Investing (Quarterly) | 201.61M |
| Cash from Financing (Quarterly) | -22.40M |
| Free Cash Flow Per Share (Quarterly) | 1.435 |
| Free Cash Flow to Equity (Quarterly) | 173.91M |
| Free Cash Flow to Firm (Quarterly) | 179.00M |
| Free Cash Flow Yield | 7.75% |